Weight decline in patients switching from olanzapine to quetiapine

Schizophrenia Research
Sanjay GuptaKari Lockwood

Abstract

This open-label study investigated the strategy of switching patients who had gained excessive weight on olanzapine to quetiapine, with assessments of safety and continued efficacy as well as weight change. Patients who were psychiatrically stable on olanzapine but had gained >20% in weight and had body mass index >25 mg/kg(2) were switched to quetiapine over a 4-week period and followed for 6 weeks, the total study duration being 10 weeks. Assessments included weight change, antipsychotic efficacy using the Positive and Negative Symptom Syndrome Scale (PANSS), extrapyramidal adverse events using the Simpson-Angus Scale (SAS), and laboratory studies for metabolic measures. Of 16 enrolled patients, 12 completed the study. Mean weight loss was 2.25 kg (Cohen's d = 0.12; P = 0.03). There were no significant changes in PANSS total scores, SAS scores, or metabolic parameters. Switching patients to quetiapine, appears to be a viable strategy for managing olanzapine-induced weight gain as indicated by this 10-week open-label study. Prospective controlled trials of longer duration and larger number of subjects are needed.

References

Jun 11, 1998·Annals of Clinical Psychiatry : Official Journal of the American Academy of Clinical Psychiatrists·S GuptaB Frank
Oct 8, 1999·The New England Journal of Medicine·E E CalleC W Heath
Nov 5, 1999·JAMA : the Journal of the American Medical Association·A MustW H Dietz
Apr 13, 2000·Archives of Internal Medicine·UNKNOWN National Task Force on the Prevention and Treatment of Obesity
May 16, 2000·The Journal of Clinical Psychiatry·G L Blackburn
Feb 24, 2001·Lancet·G J WangJ S Fowler
Mar 16, 2001·Expert Opinion on Pharmacotherapy·S Kasper, F Müller-Spahn
Mar 16, 2001·Expert Opinion on Pharmacotherapy·P S Masand
Jun 13, 2001·Pharmacotherapy·R M CarnahanP J Perry
Oct 5, 2001·Expert Opinion on Pharmacotherapy·P E KeckL M Arnold
Oct 13, 2001·European Child & Adolescent Psychiatry·K M Haapasalo-Pesu, S Saarijärvi
Feb 9, 2002·Clinical Therapeutics·Glen L StimmelVivian Lee
May 15, 2002·Journal of Clinical Psychopharmacology·Pál CzoborJeffrey A Lieberman
Dec 31, 2002·Psychoneuroendocrinology·H Nasrallah
Jul 2, 2005·Journal of Psychiatric Practice·P S Masand, S Gupta
Jul 2, 2005·Journal of Psychiatric Practice·P J Weiden

❮ Previous
Next ❯

Citations

Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Feb 4, 2009·Current Psychiatry Reports·John O BrooksOlya Krasnykh
May 19, 2007·Journal of the American Pharmacists Association : JAPhA·L Douglas RiedFarzad Rahnavard
Aug 18, 2006·Journal of the American Pharmacists Association : JAPhA·L Douglas RiedLarry M Lopez
Aug 28, 2007·The Psychiatric Clinics of North America·Deanna L KellyRobert R Conley
Jan 13, 2009·Acta Psychiatrica Scandinavica·J M Meyer, S M Stahl
Dec 12, 2012·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Alkomiet HasanUNKNOWN WFSBP Task force on Treatment Guidelines for Schizophrenia
Jan 6, 2005·The Annals of Pharmacotherapy·E Kelly Hester, Margaret R Thrower
Mar 3, 2006·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
May 14, 2008·The Australian and New Zealand Journal of Psychiatry·Sanil Rege
Nov 11, 2005·Journal of Psychopharmacology·Chris BusheJohn Pendlebury
Apr 17, 2008·Harvard Review of Psychiatry·Lauren ShinNancy Noyes
Apr 28, 2006·Current Opinion in Psychiatry·Maria A Rettenbacher

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.